Does choroidal melanoma regression correlate with chromosome 3 loss after ruthenium brachytherapy?

Abstract

The rate of choroidal melanoma regression after ruthenium-106 brachytherapy does not appear to correlate with chromosome 3 loss, suggesting that tumour thickness reduction 6 months after treatment is unlikely to predict survival.